Comments
Drug firm Jubilant Life Sciences today said its subsidiary has received final approval from the US health regulator for Bupropion Hydrochloride extended-release tablets, used for the treatment of major depressive disorder and prevention of seasonal affective disorder.
“Jubilant Pharma Ltd...has received an abbreviated new drug application (ANDA) final approval for Bupropion Hydrochloride extended-release tablets USP (XL), 150 mg and 300 mg,” Jubilant Life Sciences said in a BSE filing.
The approved product is the generic version of Wellbutrin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal affective disorder.
This is the fourth approval received by the company from the USFDA during the current financial year.
As on March 31, 2017, Jubilant Life Sciences had 81 ANDAs for oral solids filed in the US, of which 51 have been approved, the filing added.
Shares of the company were trading 0.64 per cent up at Rs 711.20 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.